Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-05-2005 | Original Paper

The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background

Authors: Hui-Chuan Sun, Zhao-You Tang, Zeng-Chen Ma, Lun-Xiu Qin, Lu Wang, Qin-Hai Ye, Jia Fan, Zhi-Quan Wu, Xin-Da Zhou

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2005

Abstract

Purpose

Second resection has been proved to be a safe and effective treatment for patients with intrahepatic recurrent HCC after primary resection; however, preoperative prognostic factors for outcome following second resection in patients with a hepatitis B virus (HBV) infection background remains to be clarified.

Methods

Fifty-seven patients with intrahepatic recurrent an HCC and HBV infection background received second resection from 1997 to 2003 in our institute. All of them were negative for anti-hepatitis C virus (HCV) and positive regarding HBV profile. Patient and tumor factors were analyzed.

Results

At the time of preparing this paper, 31 had re-recurrence and 21patients had died. No postoperative mortality was noted. The 1-, 3-, and 5-year overall survival after second resection were 69.9%, 61.2%, and 30.6%, respectively. Univariate and multivariate analysis showed that vascular invasion and time to recurrence were the independent prognostic factors for overall survival following second resection. The 3- and 4-year overall survival after second resection were 57.7% and 46.6% in patients with the presence of any of two risk factors (n=46), and 100% and 100% in those with absence of both risk factors (n=11, P=0.008).

Conclusions

Vascular invasion and time to recurrence were the prognostic factors for overall survival following second resection of intrahepatic recurrent HCC.

Arii S, Monden K, Niwano M, Furutani M, Mori A, Mizumoto M, Imamura M (1998) Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis intrahepatic metastasis and extrahepatic recurrence. J Hepatobiliary Pancreat Surg 5:86–92

Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP (2003) Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 197:753–758CrossRef

Cieslak E, Kepka L, Fijuth J, Marchel A, Kroh H (2004) Very late relapse of medulloblastoma. Folia Neuropathol 42:49–53

De Carlis L, Giacomoni A, Pirotta V, Lauterio A, Slim AO, Sammartino C, Cardillo M, Forti D (2003) Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg 196:887–897CrossRef

Esnaola NF, Mirza N, Lauwers GY, Ikai I, Regimbeau JM, Belghiti J, Yamaoka Y, Curley SA, Ellis LM, Nagorney DM, Vauthey JN (2003) Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States France and Japan. Ann Surg 238:711–719CrossRef

Gattelli A, Cirio MC, Quaglino A, Schere-Levy C, Martinez N, Binaghi M, Meiss RP, Castilla LH, Kordon EC (2004) Progression of pregnancy-dependent mouse mammary tumors after long dormancy periods. Involvement of Wnt pathway activation. Cancer Res 64:5193–5199

Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J (2000) Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg 191:381–388CrossRefPubMed

Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, Dela Torre A, Cho KC, Contractor D, Korogodsky M (2003) Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 197:759–764CrossRef

Hirohashi K, Shuto T, Kubo S, Tanaka H, Yamamoto T, Ikebe T, Murase J, Kinoshita H (2001) Prognostic factors after recurrence of resected hepatocellular carcinoma associated with hepatitis C virus. J Hepatobiliary Pancreat Surg 8:81–86CrossRef

Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228–232CrossRef

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207CrossRef

Ishii H, Okada S, Sato T, Nose H, Okusaka T, Yoshimori M, Takayasu K, Takayama T, Kosuge T, Yamasaki S (1996) Effect of percutaneous ethanol injection for postoperative recurrence of hepatocellular carcinoma in combination with transcatheter arterial embolization. Hepatogastroenterology 43:644–650

Jeng KS, Yang FS, Chiang HJ, Ohta I (1992) Repeat operation for nodular recurrent hepatocellular carcinoma within the cirrhotic liver remnant: a comparison with transcatheter arterial chemoembolization. World J Surg 16:1188–1191

Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, et al (2001) Effects of long–term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized controlled trial. Ann Intern Med 134:963–967

Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M, Sassa T (1997) Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25:87–92

Lai EC, Lo CM, Fan ST, Liu CL, Wong J (1998) Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133:183–188CrossRef

Meltzer A (1990) Dormancy and breast cancer. J Surg Oncol 43:181–188

Minagawa M, Makuuchi M, Takayama T, Kokudo N (2003) Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238:703–710CrossRef

Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, et al (1996) Prevention of second primary tumors by an acyclic retinoid polyprenoic acid in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334:1561–1567CrossRef

Nagasue N, Kohno H, Hayashi T, Uchida M, Ono T, Yukaya H, Yamanoi A (1996) Repeat hepatectomy for recurrent hepatocellular carcinoma. Br J Surg 83:127–131

Nakajima Y, Ko S, Kanamura T, Nagao M, Kanehiro H, Hisanaga M, Aomatsu Y, Ikeda N, Nakano H (2001) Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg 192:339–344CrossRef

Nicoli N, Casaril A, Marchiori L, Mangiante G, Hasheminia AR (2001) Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation. J Hepatobiliary Pancreat Surg 8:417–421CrossRef

Okazaki M, Yamasaki S, Ono H, Higashihara H, Koganemaru F, Kimura S, Kuroda Y, Sato S, Ryu K, Ohtsubo T (1993) Chemoembolotherapy for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Hepatogastroenterology 40:320–323

Poon RT, Fan ST, Lo CM, Liu CL, Wong J (1999) Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229:216–222CrossRef

Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89:500–507CrossRefPubMed

Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J (2001) Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 234:63–70CrossRef

Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002a) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235:373–382CrossRef

Poon RT, Fan ST, O’Suilleabhain CB, Wong J (2002b) Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 195:311–318CrossRef

Sugimachi K, Maehara S, Tanaka S, Shimada M (2001) Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 8:410–416CrossRef

Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807CrossRef

Tang ZY, Yu YQ, Zhou XD (1984) An important approach to prolonging survival further after radical resection of AFP positive hepatocellular carcinoma. J Exp Clin Cancer Res 3:359–366

Tang ZY, Yu YQ, Zhou XD, Ma ZC, Yang R, Lu JZ, Lin ZY, Yang BH (1989) Surgery of small hepatocellular carcinoma. Analysis of 144 cases. Cancer 64:536–541

Tang ZY, Yu YQ, Zhou XD, Ma ZC, Wu ZQ (1998) Progress and prospects in hepatocellular carcinoma surgery. Ann Chir 52:558–563PubMed

Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P’Eng F K (1995) Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 82:122–126

Yamamoto M, Arii S, Sugahara K, Tobe T (1996) Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 83:336–340CrossRef

Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347:168–174CrossRef

Title: The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background
Authors: Hui-Chuan Sun
Zhao-You Tang
Zeng-Chen Ma
Lun-Xiu Qin
Lu Wang
Qin-Hai Ye
Jia Fan
Zhi-Quan Wu
Xin-Da Zhou
Publication date: 01-05-2005
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 5/2005
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-004-0645-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2005

Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells

Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine

Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin

Characterization of the combined cellular survival effects of benzoquinone-ansamycins and ionizing radiation

New tumor necrosis factor-α-inducing protein released from Helicobacter pylori for gastric cancer progression

Reply concerning “Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma” by Terheyden et al. (2004)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials